Quality prescribing strategy for type 2 diabetes mellitus: a guide for improvement
| ACEi | angiotensin converting enzyme inhibitor |
| ADA | American Diabetes Association |
| ACR | urine albumin to creatinine ratio |
| ADR | adverse drug reactions |
| ARB | angiotensin receptor blocker |
| ASCVD | atherosclerotic cardiovascular disease e.g., angina, myocardial infarction, stroke |
| BMI | body mass index |
| BNF | British National Formulary |
| CFS | Clinical Frailty Scale |
| CKD | chronic kidney disease |
| CrCl | creatinine clearance |
| CVD | cardiovascular disease |
| DKA | diabetic ketoacidosis |
| DPP-4i | dipeptidyl peptidase-4 inhibitor e.g., alogliptin, linagliptin, sitagliptin, saxagliptin, vildagliptin |
| DSMES | diabetes self-management education and support |
| EASD | European Association for the Study of Diabetes |
| eDKA |
euglycaemic diabetic ketoacidosis |
| eGFR | estimated glomerular filtration rate |
| FGM | flash glucose monitor |
| GLP-1RA | glucagon-like peptide 1 receptor agonist e.g., dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide |
| HbA1c | glycated haemoglobin |
| (c)HF | (chronic) heart failure |
| LVH | left ventricular hypertrophy |
| MACE | major adverse cardiovascular events |
| MDD | major depressive disorder |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| NICE | National Institute for Health and Clinical Excellence |
| SG | Scottish Government |
| SGLT-2i | sodium-glucose co-transporter-2 inhibitor e.g., canagliflozin, dapagliflozin, empagliflozin |
| SIMD | Scottish Index of Multiple Deprivation |
| SMG | self-monitoring glucose |
| SU | sulfonylurea |
| TZD | thiazolidinediones e.g., pioglitazone |